Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jacc.2024.05.028 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The distinct effects of metformin and imeglimin on high glucose-induced alterations in metabolic function and reactive oxygen species production in mouse Schwann cells are modulated by pemafibrate and/or fatty acid-binding proteins.
Front Cell Neurosci
August 2025
Department of Ophthalmology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Background: Imeglimin (Ime), the first in a novel class of antidiabetic agents, has potential therapeutic effects on diabetic peripheral neuropathy (DPN). This study aimed to evaluate and compare the effects on cellular metabolic function and reactive oxygen species (ROS) levels in high glucose-treated mouse Schwann cells (SCs), an DPN model, with those of metformin (Met), a conventional antidiabetic agent known for its beneficial effects on DPN. The roles of PPARα and fatty acid-binding proteins 5 and 7 (FABP5 and FABP7), both of which have been implicated in the pathogenesis of DPN, were also investigated.
View Article and Find Full Text PDFEffect of pemafibrate on high-density lipoprotein cholesterol levels and subspecies in a patient with cholesteryl ester transfer protein deficiency: A case report with mechanistic insights.
J Clin Lipidol
July 2025
Department of Cardiology, Rinku General Medical Center, Osaka, Japan (Dr Yamashita).
Cholesteryl ester transfer protein (CETP) deficiency is a representative molecular abnormality in familial hyperalphalipoproteinemia, a hereditary disorder of lipid metabolism characterized by markedly elevated plasma high-density lipoprotein cholesterol (HDL-C) levels. In this condition, dysfunction of CETP, which mediates the transfer of cholesteryl esters from HDL particles to apolipoprotein (Apo)B-containing lipoproteins, leads to the abnormal accumulation of HDL-C. These HDL particles are unusually large and enriched in cholesteryl esters, ApoCIII, and ApoE, whereas low-density lipoprotein (LDL) particles are small, depleted of cholesteryl esters, and enriched in triglycerides.
View Article and Find Full Text PDFTreatment with pemafibrate ameliorates fatty liver index and atherogenic lipid profiles in Japanese patients with type 2 diabetes mellitus.
Front Endocrinol (Lausanne)
August 2025
Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan.
Background: Pemafibrate, a selective peroxisome proliferator-activated receptor α modulator, ameliorates hypertriglyceridemia. We investigated the effects of pemafibrate on steatotic liver disease (SLD) in relation to various atherogenic lipid profiles.
Methods: Thirty-nine Japanese patients with both type 2 diabetes mellitus (T2DM) and hypertriglyceridemia (men/women: 24/15, mean age: 58.
Long-Term Safety and Efficacy of Pemafibrate to Treat Hyperlipidemia: Post-marketing Surveillance Over a 24-Month Observation Period in Japan.
Adv Ther
July 2025
Division of Endocrinology and Metabolism, Department of Internal Medicine, School of Medicine, Jichi Medical University, Tochigi, Japan.
Introduction: Pemafibrate was well tolerated and effective in clinical trials that led to its approval to treat hyperlipidemia. However, these clinical trials typically have limitations and may not sufficiently assess the performance of pemafibrate in the real-world setting. Therefore, the aim of this study was to evaluate the long-term safety and efficacy of pemafibrate in patients with hyperlipidemia in Japan.
View Article and Find Full Text PDFEvaluation of the Short-term Effect of Pemafibrate on Liver Fibrosis Biomarkers Stratified by FIB-4 Index in Patients with Type 2 Diabetes Mellitus and Hypertriglyceridemia.
Intern Med
July 2025
Department of Diabetes/Endocrinology and Metabolism, Minoh City Hospital, Japan.
Aims This study aimed to investigate the short-term effects of pemafibrate (PEMA) on the Fibrosis-4 index (FIB-4) and Aspartate Aminotransferase to Platelet Ratio Index (APRI) across three subgroups stratified according to FIB-4 for assessing the risk of liver fibrosis in patients with type 2 diabetes (T2D) and hypertriglyceridemia. Methods A total of 114 patients were stratified into three subgroups based on their FIB-4 score at the initiation of PEMA, following the FIB-4 classification: Group 1 (G1) (FIB-4<1.30, n =46), Group 2 (G2) (FIB-4 1.
View Article and Find Full Text PDF